Intracellular genomic transplant and methods of therapy
Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
1. A pharmaceutical composition that comprises an ex vivo engineered human primary immune cell that comprises:
a) a genomic disruption within a cytokine inducible SH2-containing protein gene target sequence that comprises any one of SEQ ID NO: 75— SEQ ID NO: 86, wherein said genomic disruption comprises an endonuclease-mediated indel; and
b) at least one nucleic acid encoding an exogenous functional T cell receptor, or a functional fragment thereof, or an exogenous functional chimeric antigen receptor, or a functional fragment thereof,
wherein said exogenous functional T cell receptor, or said functional fragment thereof, or said exogenous functional chimeric antigen receptor, or said functional fragment thereof, binds a neo-antigen expressed by a cancer cell, and wherein said neoantigen arises from a somatic mutation.
2. The pharmaceutical composition of claim 1 , wherein said ex vivo engineered human primary immune cell expresses said exogenous functional T cell receptor, or said functional fragment thereof, or said exogenous functional chimeric antigen receptor, or said functional fragment thereof.
3. The pharmaceutical composition of claim 1 , wherein said cytokine inducible SH2-containing protein gene sequence comprises a nucleic acid sequence with at least 90% identity to SEQ ID NO: 103.
4. The pharmaceutical composition of claim 1 , wherein said ex vivo engineered human primary immune cell further comprises a genomic disruption in a T Cell Receptor Alpha Constant gene sequence or a T Cell Receptor Beta Locus gene sequence.
5. The pharmaceutical composition of claim 4 , wherein said at least one nucleic acid encoding said exogenous functional T cell receptor, or said functional fragment thereof, or said exogenous functional chimeric antigen receptor, or said functional fragment thereof, is integrated into said genomic disruption in said T Cell Receptor Alpha Constant gene sequence or said T Cell Receptor Beta Locus gene sequence.
6. The pharmaceutical composition of claim 1 , wherein said ex vivo engineered human primary immune cell is selected from the group consisting of a T cell, a dendritic cell, a B cell, and a natural killer cell.
7. The pharmaceutical composition of claim 1 , wherein said ex vivo engineered human primary immune cell is a tumor infiltrating lymphocyte or a peripheral blood lymphocyte.
8. The pharmaceutical composition of claim 1 , wherein said genomic disruption is performed by a Clustered Regularly Interspaced Short Palindromic Repeats system.
9. The pharmaceutical composition of claim 1 , wherein said cancer cell is from a cancer selected from the group consisting of: bladder cancer, epithelial cancer, bone cancer, brain cancer, breast cancer, esophageal cancer, gastrointestinal cancer, leukemia, liver cancer, lung cancer, lymphoma, myeloma, ovarian cancer, prostate cancer, sarcoma, stomach cancer, thyroid cancer, acute lymphocytic cancer, acute myeloid leukemia, alveolar rhabdomyosarcoma, anal cancer, rectal cancer, ocular cancer, cancer of the neck, gallbladder cancer, pleural cancer, oral cancer, cancer of the vulva, colon cancer, cervical cancer, fibrosarcoma, gastrointestinal carcinoid tumor, Hodgkin lymphoma, kidney cancer, mesothelioma, mastocytoma, melanoma, multiple myeloma, nasopharynx cancer, non-Hodgkin lymphoma, pancreatic cancer, peritoneal cancer, renal cancer, skin cancer, small intestine cancer, testicular cancer, and thyroid cancer.
10. The pharmaceutical composition of claim 1 , wherein said at least one nucleic acid is a deoxyribonucleic acid.
11. The pharmaceutical composition of claim 1 , wherein said at least one nucleic acid encoding said exogenous functional T cell receptor, or said functional fragment thereof, or said exogenous functional chimeric antigen receptor, or said functional fragment thereof, is integrated into a gene sequence of the human primary immune cell.
12. The pharmaceutical composition of claim 1 , wherein said at least one nucleic acid encoding said exogenous functional T cell receptor, or said functional fragment thereof, or said exogenous functional chimeric antigen receptor, or said functional fragment thereof, is integrated into said genomic disruption in said cytokine inducible SH2- containing protein gene sequence.
13. The pharmaceutical composition of claim 1 , wherein said at least one nucleic acid encoding said exogenous functional T cell receptor, or said functional fragment thereof, or said exogenous functional chimeric antigen receptor, or said functional fragment thereof, is integrated into a genomic disruption in a T Cell Receptor Alpha Constant gene sequence or a genomic disruption in a T Cell Receptor Beta Locus gene sequence.
14. The pharmaceutical composition of claim 1 , wherein said at least one nucleic acid encoding said exogenous functional T cell receptor, or said functional fragment thereof, or said exogenous functional chimeric antigen receptor, or said functional fragment thereof, is introduced into said ex vivo engineered human primary immune cell using a viral vector.
15. The pharmaceutical composition of claim 14 , wherein said viral vector is an adeno-associated virus vector.
16. A pharmaceutical composition that comprises an ex vivo engineered human primary immune cell that comprises:
a) a genomic disruption within a cytokine inducible SH2-containing protein gene target sequence that comprises any one of SEQ ID NO: 75— SEQ ID NO: 86, wherein said genomic disruption comprises an endonuclease-mediated indel; and
b) at least one nucleic acid encoding an exogenous functional T cell receptor, or a functional fragment thereof, or an exogenous functional chimeric antigen receptor, or a functional fragment thereof,
wherein said exogenous functional T cell receptor, or said functional fragment thereof, or said exogenous functional chimeric antigen receptor, or said functional fragment thereof, binds a neo-antigen expressed by a breast cancer cell.
17. The pharmaceutical composition of claim 16 , wherein said neoantigen arises from a somatic mutation.